Table 1.
Preclinical pharmacokinetics of 326E in mice and dogs.
| Species | Route | Dose (mg/kg) | CL (mL/min/kg) | Vss (L/kg) | t1/2 (h) | Tmax (h) | Cmax (μg/mL) | AUC0–t (μg·h/mL) |
|---|---|---|---|---|---|---|---|---|
| ICR mice | iv | 10 | 1.31 | 0.33 | 4.55 | NA | NA | 138.00 |
| po | 10 | NA | NA | 3.79 | 0.13 | 25.65 | 128.40 | |
| Beagle dog | iv | 5 | 0.13 | 0.29 | 26.20 | NA | NA | 534.00 |
| po | 5 | NA | NA | 27.40 | 0.25 | 39.60 | 419.00 |
Pharmacokinetic parameters were calculated from plasma concentration-time data and were reported as mean value (n = 6, sex in half). Solution formulation for iv pharmacokinetics were conducted using ddH2O. Oral pharmacokinetics were conducted using 0.9% NaCl. NA = not applicable.